Washington, DC —The Alliance for Regenerative Medicine (ARM), the political voice for regenerative medicine, today reported significant progress toward its policy and membership objectives since its formation in September 2009. ARM’s achievements include an upcoming meeting with U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, M.D., as well as a doubling of its membership to include 50 members.
“We have made enormous progress in establishing ARM’s visibility with legislators and regulators, and are working to supply them with pivotal information and education that they can use as a basis for decision making,” said Michael Werner, ARM’s Co-Founder and Executive Director and a Partner at Holland & Knight. “We are delighted with the reception ARM has received thus far, and it confirms our belief that the time is right for a unified endeavor to support regenerative medicine,” Mr. Werner added.
“ARM is fortunate to have the participation of many of the most experienced, dedicated industry leaders and researchers in the regenerative medicine community among our members,” said Morrie Ruffin, Co-Founder and Managing Director of ARM and Managing Director of Adjuvant Global Advisor. “We are pleased to welcome our new members, and invite every stakeholder to the table to participate with ARM in shaping the future of regenerative medicine, a field which has the potential to transform human health.”
“ARM has rapidly established itself as an influential force for regenerative medicine, and on behalf of the membership we are thankful that our industry now has strong representation,” said John Walker, Chairman of ARM and Chief Executive Officer of iPerian.
ARM’s agenda encompasses funding, policy, regulation, reimbursement, communication and education around issues pertaining to regenerative medicine, including access to life-saving stem-cell therapies. ARM carries out its mission through its Executive, Government Relations & Policy, Regulatory & Reimbursement and Communication & Education committees.